Ionis Pharmaceuticals (LTS:0JDI) Common Stock : $0.1 Mil (As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Common Stock?

Ionis Pharmaceuticals's quarterly common stock increased from Sep. 2023 ($0.1 Mil) to Dec. 2023 ($0.1 Mil) and increased from Dec. 2023 ($0.1 Mil) to Mar. 2024 ($0.1 Mil).

Ionis Pharmaceuticals's annual common stock increased from Dec. 2021 ($0.1 Mil) to Dec. 2022 ($0.1 Mil) and increased from Dec. 2022 ($0.1 Mil) to Dec. 2023 ($0.1 Mil).

Ionis Pharmaceuticals Common Stock Historical Data

The historical data trend for Ionis Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Common Stock Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.14

Ionis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.14	0.14	0.14	0.14	0.15

Ionis Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Ionis Pharmaceuticals (LTS:0JDI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (LTS:0JDI) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

IONS:USA IONS:Mexico ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (LTS:0JDI) Headlines

No Headlines